|[December 20, 2012]
Radius, 3M Drug Delivery Systems Announce Exclusive Agreement for Development, Commercialization of Transdermal Delivery of BA058 for Osteoporosis
CAMBRIDGE, Mass. --(Business Wire)--
Health, Inc. ("Radius") and 3M (News - Alert) Drug Delivery Systems are
pleased to announce an exclusive partnership agreement for development
and commercialization of BA058-transdermal (TD). BA058 is a novel,
synthetic proprietary peptide analog of human parathyroid hormone
related protein or "hPTHrP," a bone building anabolic compound with the
potential to treat patients with osteoporosis at high risk of fracture.
This agreement updates the general development agreement announced in
May 2011 by the two companies for BA058-TD.
The BA058-TD patch applicator prototype. (Photo: Business Wire)
BA058-transdermal (TD) is being studied in a Phase 2 clinical trial in
healthy postmenopausal women with osteoporosis at 10 clinical centers.
BA058-TD is a short-wear time patch based on 3M's patented
Microstructured Transdermal System technology. The transdermal patch is
expected to combine ease of use, convenience and self-administration
attributes of a patch with the bone building efficacy of the BA058
"We are excited that 3M Drug Delivery Systems, which has long
demonstrated a commitment to quality, safety and innovation, is
partnering with us to bring a novel approach of drug delivery to the
underserved osteoporosis patient population," said Michael Wyzga, Radius
president and chief executive officer. "Our study data for BA058-TD
showed that a five-minute wear time of the patch delivers peak drug
levels consistent with subcutaneous injection and we hope to see
increased patient compliance with 3M's innovative technology."
3M Drug Delivery Systems has partnered with pharmaceutical companies
worlwide for more than 50 years, providing customized solutions to drug
"We are pleased to be part of Radius' mission of advancing therapeutics
for healthy aging with its deep expertise in osteoporosis," said Ingrid
Blair, MTS (News - Alert)/TDD business vice president of 3M Drug Delivery Systems.
"With this exclusive agreement, 3M and Radius demonstrate our commitment
to this innovative therapeutic treatment and this unique drug delivery
mechanism. We believe this new drug potentially will improve the health
of patients with severe osteoporosis and that 3M's microneedle patch
technology may improve medication compliance among patients."
BA058 is also being studied as a daily subcutaneous injection (BA058-SC)
in a Phase 3 study with 2,400 patients for fracture prevention in women
with postmenopausal osteoporosis at high risk of fracture. Phase 2 human
testing of the injectable BA058-SC showed that BA058 significantly
increased bone mineral density (BMD) at the lumbar spine and femoral
neck (a common osteoporotic fracture site located in the hip joint)
after six months of therapy.
Radius is a biopharmaceutical company focused on developing and
commercializing advanced therapeutics to support healthy aging. We
aspire to improve the quality of life in older adults by treating
Radius is committed to the development of advanced therapeutics for the
large and underserved osteoporosis market. The Company's lead product
candidate, BA058-SC, is in development to reduce the risk of
complications associated with osteoporosis, such as fracture. In Phase 2
trials, BA058-SC has demonstrated an effect on building bone. The
Company also has a next-generation transdermal patch, BA058-TD, being
developed as a short wear-time delivery vehicle intended to improve
patient compliance with convenience and ease of use, as well as a
product in development to treat symptoms associated with menopause.
About 3M Drug Delivery Systems
3M Drug Delivery Systems partners with pharmaceutical and biotech
companies to develop pharmaceuticals using 3M's inhalation or
transdermal drug delivery technology including microneedles. 3M offers a
full range of feasibility, development and manufacturing capabilities
combined with regulatory guidance to help bring products to market.
In-house resources, including toxicology, regulatory expertise, quality
assurance, operations, and marketed product support, are available for
each step of the development and commercialization process. This depth
of resources is one reason why more than 50 percent of all metered-dose
inhalers worldwide and 60 percent of all transdermal systems in the
United States utilize 3M drug delivery technology. For more information,
please visit www.3M.com/dds
or call 1-800-643-8086.
3M captures the spark of new ideas and transforms them into thousands of
ingenious products. Our culture of creative collaboration inspires a
never-ending stream of powerful technologies that make life better. 3M
is the innovation company that never stops inventing. With $30 billion
in sales, 3M employs about 84,000 people worldwide and has operations in
more than 65 countries. For more information, visit www.3M.com
or follow @3MNews on Twitter (News - Alert).
3M is a trademark of 3M Company.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20121220006422/en/
[ Back To TMCnet.com's Homepage ]